Treatment of Smoking Among Individuals with PTSD

创伤后应激障碍 (PTSD) 患者吸烟的治疗

• 批准号: 7690281
• 负责人: EDNA B FOA
• 金额: $ 63.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7690281
• 关键词: Abstinence; Address; Affect; Alcohol dependence; Anger; Anxiety; Applications Grants; Area; Arousal; Behavior; Bupropion; Cessation of life; Chronic; Chronic Post Traumatic Stress Disorder; Cigarette; Classification; Comorbidity; Consumption; Data; Dependence; Development; Disease; Distress; Epidemiology; Fright; Guidelines; Health Policy; Individual; Institute of Medicine (U.S.); International; Lead; Life; Light; Maintenance; Measures; Mental disorders; Naltrexone; Nicotine; Nicotine Dependence; Outcome Measure; Persons; Pharmaceutical Preparations; Pharmacotherapy; Pilot Projects; Placebos; Population; Post-Traumatic Stress Disorders; Prevalence; Process; Psychological reinforcement; Psychopathology; Psychotherapy; Public Health; Publishing; Randomized; Randomized Controlled Clinical Trials; Randomized Controlled Trials; Recommendation; Recording of previous events; Relapse; Research; Research Design; Risk; Risk Factors; Role; Smoke; Smoker; Smoking; Smoking Cessation Intervention; Staging; Study models; Substance Use Disorder; Surveys; Symptoms; Testing; Theoretical model; Time; Tobacco Dependence; Withdrawal; Withdrawal Symptom; Withholding Treatment; base; cigarette smoking; cognitive behavior therapy; combat; comparative efficacy; cost effectiveness; dependence relapse; depression; drinking; evidence base; experience; follow-up; improved; innovation; model development; multi-site trial; nicotine craving; placebo controlled study; premature; primary outcome; programs; public health relevance; secondary outcome; smoking cessation; smoking prevalence; success; treatment program; varenicline

DESCRIPTION (provided by applicant): This study will evaluate an innovative program for smokers with Post-Traumatic Stress Disorder (PTSD) that integrates the most effective medication for smoking cessation (varenicline) with prolonged exposure (PE), a highly efficacious cognitive behavioral therapy for PTSD. The development of specifically tailored and more efficacious smoking cessation treatments for smokers with psychiatric disorders, whose cigarette smoking is disproportionately high, has been identified as a high priority in public health policy. PTSD is a common mental disorder with a lifetime prevalence of 6.8%. The prevalence of smoking in people with current PTSD is 44.6% -- double the rate of those with no history of a psychological disorder (22.5%). Smokers with PTSD are more likely to be nicotine dependent, smoke heavily, experience more severe withdrawal symptoms, and relapse after a quit attempt. In fact, the quit rate for smokers with PTSD is among the lowest compared to other mental disorders. Factors that may contribute to smokers' progression to nicotine dependence and relapse include negative affect, fear, anxiety sensitivity, increased arousal, irritability, and anger. Therefore, the integration of treatment for smoking cessation with treatment for PTSD that reduces these factors is hypothesized to improve success of smoking cessation about smokers with PTSD. To test this hypothesis, we will randomly assign smokers with PTSD to either the "best practice" pharmacotherapy for smoking cessation (varenicline) alone or to a treatment that integrates varenicline with PE. The primary outcome measure will be biochemically confirmed abstinence rates at the end of treatment and at follow-up 6-months post quit date. Secondary outcome measures will be continuous abstinence, prolonged abstinence, and time to relapse. We will also obtain measures of PTSD and associated psychopathology (e.g. depression and anxiety) and risk factors (e.g. anxiety sensitivity). Collectively, our research group has expertise in the development of efficacious treatments for PTSD, including PE (Foa, Cahill, Hembree), the epidemiology of smoking and psychiatric disorders (Breslau), and smoking cessation (Lerman, O'Brian, Gariti). The proposed research affords a unique opportunity to combine experts from diverse areas with the aim of developing an innovative, integrated approach to the treatment of people who are likely to fail using existing treatments. PUBLIC HEALTH RELEVANCE: Cigarette smoking is the single most preventable cause of premature death in the US; approximately 50% of long-term smokers die of a disease caused by their dependence, shortening lives by an average of 13-14 years. Smokers with Post Traumatic Stress Disorder (PTSD) are more likely to be nicotine dependent, to smoke heavily (25 cigarettes per day or more), experience more severe withdrawal symptoms, and relapse following a quit attempt than smokers without PTSD. In this grant application, we propose to evaluate an innovative treatment program for smokers with PTSD that integrates varenicline, the most effective medication for smoking cessation, with prolonged exposure therapy, a highly effective form of psychotherapy for PTSD.

描述（由申请人提供）：本研究将评估一项针对创伤后应激障碍（PTSD）吸烟者的创新计划，该计划将最有效的戒烟药物（伐尼克兰）与长期暴露（PE）相结合，这是一种非常有效的PTSD认知行为疗法。针对吸烟比例过高的精神疾病吸烟者开发专门定制的更有效的戒烟治疗方法已被确定为公共卫生政策的高度优先事项。PTSD是一种常见的精神障碍，终生患病率为6.8%。目前患有PTSD的人中吸烟的患病率为44.6%，是没有心理障碍史的人（22.5%）的两倍。患有创伤后应激障碍的吸烟者更有可能依赖尼古丁，大量吸烟，经历更严重的戒断症状，并在戒烟尝试后复发。事实上，与其他精神疾病相比，患有PTSD的吸烟者的戒烟率是最低的。可能导致吸烟者发展为尼古丁依赖和复发的因素包括负面影响、恐惧、焦虑敏感性、唤醒增加、易怒和愤怒。因此，假设戒烟治疗与减少这些因素的PTSD治疗的整合可以提高患有PTSD的吸烟者戒烟的成功率。为了验证这一假设，我们将随机分配患有PTSD的吸烟者接受单独戒烟的“最佳实践”药物治疗（伐尼克兰）或将伐尼克兰与PE相结合的治疗。主要结局指标将是治疗结束时和戒烟后6个月随访时经生化证实的戒烟率。次要结局指标为持续戒断、延长戒断和复发时间。我们还将获得PTSD和相关精神病理学（例如抑郁和焦虑）和风险因素（例如焦虑敏感性）的测量结果。总的来说，我们的研究小组在开发PTSD的有效治疗方面具有专业知识，包括PE（Foa，Cahill，Hembree），吸烟和精神疾病的流行病学（Breslau）和戒烟（Lerman，O 'Brian，Gariti）。拟议的研究提供了一个独特的机会，联合收割机专家从不同领域的目的是开发一个创新的，综合的方法来治疗的人谁是可能失败的使用现有的治疗。 公共卫生关系：在美国，吸烟是导致过早死亡的唯一最可预防的原因;大约50%的长期吸烟者死于由其依赖引起的疾病，平均缩短寿命13-14年。患有创伤后应激障碍（PTSD）的吸烟者比没有PTSD的吸烟者更容易依赖尼古丁，大量吸烟（每天25支或更多），经历更严重的戒断症状，并在戒烟尝试后复发。在这项拨款申请中，我们建议评估一项针对患有PTSD的吸烟者的创新治疗计划，该计划将最有效的戒烟药物伐尼克兰与长期暴露疗法相结合，这是一种非常有效的PTSD心理疗法。